Transdermal Or Percutaneous Patents (Class 424/449)
  • Patent number: 11648215
    Abstract: A hydrophilic active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The system may be used to deliver/release hydrophilic active molecules that are incompatible to each other.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: May 16, 2023
    Inventor: Lei Liu
  • Patent number: 11638809
    Abstract: A transdermal delivery system for delivery of a triptan into a tissue membrane of a subject. The system includes a transdermal microporation apparatus for heating a skin surface and a triptan drug delivery patch. The drug delivery patch comprises a top layer comprising an adhesive, a middle layer comprising the triptan, and a bottom layer. A method for treating a subject comprises identifying a subject having a migraine, using the transdermal microporation apparatus to open a plurality of micropores in the skin of the subject, and applying the triptan drug delivery patch to the subject's skin over the micropores for a period of time effective to deliver the triptan through the micropores in an amount effective to treat the subject's migraine.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: May 2, 2023
    Assignee: Passport Technologies, Inc.
    Inventors: Hirotoshi Adachi, Shohei Horie, Akinori Hanatani, Masato Nishimura, Yuki Yamada, Joe Hua
  • Patent number: 11628156
    Abstract: Provided is a therapeutic product comprising at least one cannabinoid; at least one primary terpene; and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also provided is a method of treating certain conditions and/or symptoms in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a product comprising at least one primary terpene. Further provided is a therapeutic product comprising a primary terpene blend, wherein said primary terpene blend comprises five or less terpenes, and wherein each one of those terpenes, where present, independently comprises at least 10% of the total terpene content.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: April 18, 2023
    Inventors: Noa Raz, Aharon M. Eyal
  • Patent number: 11622944
    Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a-CH?CH—(CH 2)5-a-H where a is from 0 to 5, —(CH2)b-CH?CH—(CH 2)6-b-H where b is from 0 to 6, —(CH2)c-CH?CH—(CH 2)7-c-H where c is from 0 to 7, —(CH2)d-CH?CH—(CH 2)8-d-H where d is from 0 to 8, or —CH2)e-CH?CH—(CH 2)9-d-H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: April 11, 2023
    Inventors: Babak Ghalili, Arthur Goldberg, John Borja
  • Patent number: 11612572
    Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: March 28, 2023
    Inventor: Sharon Anavi-Goffer
  • Patent number: 11596779
    Abstract: A two-part bioactive agent delivery system includes a disposable part, a reusable part, and a solvent removal element. The disposable part includes an agent reservoir, a transdermal patch communicating with the agent reservoir and adapted to transdermally deliver the bioactive agent to a user. The transdermal patch has a bottom surface adapted to contact skin of the user, a top surface opposite the bottom surface, and a gas permeable membrane disposed over the top surface of the transdermal patch. The reusable part includes a power source and control electronics that are adapted to deliver bioactive agent dissolved in a solvent from the agent reservoir to the transdermal patch. The solvent removal element includes a gap disposed between the disposable part and the reusable part to create a flow path for gaseous solvent to flow from the gas permeable membrane to ambient air around the bioactive agent delivery system.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 7, 2023
    Assignee: Morningside Venture Investments Limited
    Inventors: Ling-Kang Tong, Daniela Tamar Buchman, Jackie Joe Hancock, Nicholas Terzulli
  • Patent number: 11576818
    Abstract: This disclosure includes negative pressure wound therapy dressings with local oxygen generation for topical wound therapy. The dressings (18) for facilitating delivery of oxygen and application of negative pressure to target tissue include a manifold (46) that defines a plurality of gas passageways (50) and is configured to allow communication of oxygen to the target tissue; an oxygen-generating material (146) that is configured to release oxygen when exposed to water; a gas-occlusive layer (74) configured to be disposed over the manifold and the oxygen-generating material and coupled to tissue surrounding the target tissue such that an interior volume containing the manifold and the oxygen-generating material is defined between the gas-occlusive layer and the target tissue; and a port (94) coupled to the gas-occlusive layer and configured to be coupled to a negative pressure source.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 14, 2023
    Inventors: Justin Alexander Long, Christopher Brian Locke, Timothy Mark Robinson, Richard Coulthard
  • Patent number: 11576874
    Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: February 14, 2023
    Assignees: LTS LOHMANN Therapie-Systeme AG, DDP Specialty Electronic Materials US 9, LLC
    Inventors: Marco Emgenbroich, Eva-Marie Prinz, Elke Klein, Heike Kluth, Xavier Thomas, Linda Sue Nartker
  • Patent number: 11541004
    Abstract: A method for treating or mitigating Parkinson's disease (PD) symptoms or progression, including administering an effective amount of nicotine to a subject in need thereof, via inhalation using a nicotine inhaler or via nasal spray using a nicotine nasal spray. Significant dose-dependent improvement of all symptoms by nicotine inhaler or nicotine nasal spray is expected. A novel treatment in PD is thus provided.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 3, 2023
    Inventors: Yousef Tizabi, Robert L. Copeland
  • Patent number: 11523994
    Abstract: The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: December 13, 2022
    Inventors: Yogesh Dandiker, Maulik Kiritkumar Panchal
  • Patent number: 11504413
    Abstract: A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: November 22, 2022
    Assignee: Exerkine Corporation
    Inventors: Stuart Phillips, Gianni Parise, Jennifer Heisz
  • Patent number: 11478434
    Abstract: The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: October 25, 2022
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Reinhold Meconi, Klaus Schumann
  • Patent number: 11464956
    Abstract: A microneedle device of the present invention comprises a substrate, microneedles disposed on the substrate, and a coating layer formed on the microneedles, wherein a length of the microneedles is 300 to 500 ?m, the microneedles are disposed on the substrate at a density of 28 to 80 needles/cm2, and the coating layer comprises a biologically active substance. The microneedle device allows the skin irritation caused by administration of an agent to be reduced.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: October 11, 2022
    Inventors: Kazuya Machida, Shinpei Nishimura, Seiji Tokumoto
  • Patent number: 11446363
    Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 20, 2022
    Assignee: Hybrid Medical, Inc.
    Inventors: Jeffry Twidwell, Joel Buckley, Harold Hoium
  • Patent number: 11426359
    Abstract: The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: August 30, 2022
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Marco Emgenbroich, Johannes Josef Leonhard, Hans-Michael Wolff
  • Patent number: 11413247
    Abstract: The present invention relates to a melt extrusion process for preparing a solid dispersion comprising a pharmaceutically active ingredient, a polymeric binder, and, optionally, one or more auxiliary agents, comprising a) in a batch-wise operation, placing a pre-determined amount of the polymeric binder, a pre-determined amount of the active ingredient, and, optionally, a pre-determined amount of the auxiliary agent(s) in a melting vessel; melting the polymeric binder with agitation to disperse the active ingredient in the polymeric binder to obtain a molten pre-dispersion; b) feeding the pre-dispersion into an extruder to homogenize the pre-dispersion and release a melt through a die; and c) allowing the melt to solidify.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: August 16, 2022
    Inventor: Tiziana Adage
  • Patent number: 11407648
    Abstract: The present invention relates to a process for preparing a formulation comprising an alkali metal salt selected from the group consisting of alkali metal bicarbonate salts, alkali metal carbonate salts, alkali metal sesquicarbonate salts and combinations thereof, wherein said process comprises the step of extruding a paste-like composition comprising a functionalizing agent and the metal salt. The invention furthermore relates to a formulation obtainable from said process and to the use of this formulation in various applications such as in plastic foaming or in food and feed leavening compositions.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: August 9, 2022
    Assignee: Solvay SA
    Inventors: Jorge Alejandro Kabbabe Malave, Thibaud Detoisien, Karine Cavalier
  • Patent number: 11382870
    Abstract: The present invention provides a risperidone-containing patch having an excellent drug release property and patch physical properties. Specifically, the present invention provides a medical patch comprising an adhesive composition comprising risperidone or a pharmaceutically acceptable salt thereof; a carboxylic acid; a fatty acid ester; and an adhesive, characterized in that said adhesive is a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a sulfur residue of a mercapto group situated at the center, wherein the (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.99% by mass of the whole structural units in said star-shaped acrylic block polymer, and at least one of said chain polymer portions has a structural unit having a copolymer structure of polymerizable monomers comprising a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a polyfunctional monomer.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 12, 2022
    Inventors: Satoshi Kawakami, Manabu Sogabe, Taiki Shibata, Hiroaki Hasegawa
  • Patent number: 11382869
    Abstract: Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: July 12, 2022
    Inventor: Suresh Borsadia
  • Patent number: 11383084
    Abstract: Methods for treating a subject for a dermatological condition are provided. Aspects of the invention include administering an effective amount of a neuromodulatory agent to a subject to treat the subject for the dermatological condition. Also provided are compositions, kits and systems for practicing the subject methods.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 12, 2022
    Assignee: Palo Alto Investors
    Inventors: Anthony Joonkyoo Yun, Kimberly A. Bazar, Conrad Minkyoo Yun
  • Patent number: 11364207
    Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, and the mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: June 21, 2022
    Inventors: Hideaki Ohashi, Takito Shima, Kenji Ishigaki, Yasunari Michinaka
  • Patent number: 11344491
    Abstract: The present disclosure provides compositions comprising decontaminating compounds, and pharmaceutically acceptable salts thereof and methods of treating or preventing a contamination in a mammal, in particular, the composition can include a mixture of polyvinyl acetate and povidone, a coblock polymer of ethylene oxide and propylene oxide, a polyvinyl alcohol, or combinations thereof, and an aqueous suspending agent.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 31, 2022
    Inventors: Howard I. Maibach, Xiaoying Hui, Hanjiang Zhu
  • Patent number: 11337940
    Abstract: Compositions and methods to produce adhesive articles with active agents concentrated at the substrate contacting surface. The active agents are applied in powder form, or in combination with a liquid or gel vehicle, to the substrate contacting surface of an adhesive layer of an adhesive article. The active agent compositions are directly applied to the adhesive layer, or are first applied to a release liner, which is then brought into contact with the adhesive layer to dispose the active agent compositions to the substrate contacting surface of the adhesive layer. Upon application of the adhesive article to a substrate, the active agent is delivered to a region of interest on the substrate.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: May 24, 2022
    Assignee: Avery Dennison Corporation
    Inventors: Anna Andrews, Rachel Shi, Anne Marie Wibaux, Emily Berlin
  • Patent number: 11318468
    Abstract: A blister assembly comprises at least one collapsible blister adapted, as it is collapsed, to eject a liquid contained therein. The blister assembly comprises a first layer (130) having at least one blister chamber (150) and a second layer (131) sealed to the first layer at least around a periphery of the at least one blister chamber such that a liquid is contained between the first layer and the second layer. The seal between the first and second layers comprises a first planar portion having a first peel strength and a second planar portion having a second peel strength, wherein the first peel strength is greater than the second peel strength, such that when pressure is applied to the blister, the second portion of the seal breaks to release the liquid contained within the chamber into the liquid inlet.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: May 3, 2022
    Assignee: Binx Health Limited
    Inventor: Tom Edwards
  • Patent number: 11304912
    Abstract: The present application relates to a transdermal therapeutic system comprising a backing layer impermeable to active substances and a polymer matrix on one side of the backing layer impermeable to active substances, wherein the polymer matrix comprises at least one pharmaceutically active substance, at least one inherently non-self-adhesive polymer and at least one plasticizer, said polymer matrix being free of adhesive polymers. The invention further relates to a method of producing the transdermal therapeutic system and to the use thereof as a drug.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 19, 2022
    Inventors: Michael Linn, Markus Müller, Marius Bauer
  • Patent number: 11291730
    Abstract: A composition for treating a wound includes graphene oxide (GO) and hyaluronic acid (HA) that are covalently linked, XAV939, and water. The composition can also include a surfactant, such as PEG. The composition can be topically administered to a subject to treat a wound of the subject. Methods of treating a wound using the composition are also provided.
    Type: Grant
    Filed: October 6, 2018
    Date of Patent: April 5, 2022
    Assignee: ELUCIDERM INC.
    Inventor: Daniel D Holsworth
  • Patent number: 11278549
    Abstract: A method of treating obesity and obesity-related disorders in a mammal is provided. The method comprises the step of administering to the mammal a compound or entity that inhibits the HTR2a receptor.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 22, 2022
    Assignee: McMaster University
    Inventors: Gregory Steinberg, Alex Green
  • Patent number: 11247226
    Abstract: A process capable of commercial scale manufacturing of inexpensive, multilayered shaped film product, without the waste of die-cutting and which products are capable of use independent of a supporting structure on which they are formed, includes placing a first mask over a substrate; delivering a first film-forming composition through the first mask to form a first raw shape on the substrate; removing the first mask; placing a second mask over the first raw shape; delivering a second film-forming composition through the second mask to form a second raw shape on the first raw shape; removing the second mask; and solidifying the first and second raw shapes to provide the shaped film product disposed on the substrate.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: February 15, 2022
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Curt Binner, Kenneth A. Pelley
  • Patent number: 11219631
    Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: January 11, 2022
    Assignee: Vyne Pharmaceuticals Inc.
    Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
  • Patent number: 11207297
    Abstract: The present invention relates to liquid pharmaceutical composition suitable for oral administration comprising clonidine or pharmaceutically acceptable salts thereof with at least one buffer and at least one preservative. The present invention also relates to process for preparing the said liquid pharmaceutical composition.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: December 28, 2021
    Assignee: SYRI LTD.
    Inventors: Kamlesh Patel, Sanjaykumar Maganbhai Patel, Viral Mahendrabhai Patel
  • Patent number: 11206824
    Abstract: The present invention relates to a gas delivery device comprising a gas releasing molecule and a gas permeable membrane. The invention also relates to the use of the gas delivery device for delivery of gas to an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff and in therapy. The invention further relates to the use of a gas permeable and liquid and solid impermeable membrane to separate a gas releasing molecule and its non-gaseous degradation products from an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: December 28, 2021
    Assignee: Julius-Maximilians-Universitaet Wuerzburg
    Inventors: Lorenz Meinel, Christoph Steiger, Christian Wunder
  • Patent number: 11202764
    Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains a rubber-based adhesive base and a silicone-based adhesive base, and a mass ratio of the rubber-based adhesive base to the silicone-based adhesive base (the mass of the rubber-based adhesive base:the mass of silicone-based adhesive base) in the adhesive layer is 9.5:0.5 to 1.9:8.1.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 21, 2021
    Inventors: Kazuya Kominami, Takito Shima, Naoyuki Uchida, Naoko Fujita, Shigeo Suzuki, Terumitsu Kaiho
  • Patent number: 11198800
    Abstract: A method of inverting the phase arrangement of the silicone phase and the acrylic phase in a silicone acrylic hybrid composition, the silicone acrylic hybrid composition comprising: a) a silicone acrylic hybrid pressure sensitive adhesive, and b) a solvent, wherein the phase arrangement of the silicone phase and the acrylic phase in the initial silicone acrylic hybrid composition forming a continuous external phase and a discontinuous internal phase is determined by the solvent, comprising the step of adding an activator to the silicone acrylic hybrid composition, wherein the activator a) is liquid at 20° C. and 1013 mbar, b) has a boiling point which is higher than the boiling point of the solvent and/or has a vapor pressure at 20° C.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: December 14, 2021
    Inventor: Marco Emgenbroich
  • Patent number: 11198741
    Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: December 14, 2021
    Inventors: Matteo D'Este, Giovanni Gennari
  • Patent number: 11179324
    Abstract: Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active agents.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: November 23, 2021
    Inventors: Mahmoud Ameri, Michel J. N. Cormier, Scott Sellers, Yuh-Fun Maa
  • Patent number: 11179346
    Abstract: An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 23, 2021
    Inventors: Satoshi Kawakami, Manabu Sogabe
  • Patent number: 11160764
    Abstract: The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a patch which shows excellent adhesion to the skin even when drugs and other additives are dissolved into the composition.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 2, 2021
    Assignees: Medherant Limited, Bostik SA
    Inventors: David Haddleton, David Goubard, Ciaran O'Driscoll
  • Patent number: 11160744
    Abstract: A gel composition containing (a) at least one selected from tocopherol phosphoric acid esters and salts thereof; (b) carrageenan; (c) locust bean gum; (d) at least one selected from agar and glucomannan; and e) water.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 2, 2021
    Assignee: SHOWA DENKO K.K.
    Inventors: Natsuno Mishina, Naoko Ito, Manami Hatano, Risa Iguchi
  • Patent number: 11147790
    Abstract: Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: October 19, 2021
    Assignee: Verrica Pharmaceuticals Inc.
    Inventors: Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
  • Patent number: 11129807
    Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: September 28, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
  • Patent number: 11090265
    Abstract: The purpose of the present invention is to provide an aqueous preparation for external use, said aqueous preparation comprising an acidic drug such as an arylacetic acid nonsteroidal anti-inflammatory analgesic, having an excellent percutaneous absorbability and giving a good feeling in use. The aqueous preparation for external use comprises the acidic drug or a salt thereof, isostearic acid and an alkanol amine. It is preferred that the aqueous preparation according to the present invention for external use further comprises a C2-6 aliphatic hydroxy acid and has a pH value of 4.5-7.8. The C2-6 aliphatic hydroxy acid is one member or a combination of the same selected from the group consisting of lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: August 17, 2021
    Assignee: MEDRX CO., LTD.
    Inventor: Katsuhiro Yamanaka
  • Patent number: 11058651
    Abstract: A topical composition for nociceptive and neuropathic pain relief comprising one or more of menthol, camphor, methyl sulfonyl methane, lidocaine, Arinica montana, harpagophytum tincture, Emu oil, maqui powder, turmeric oil and in some embodiments methyl salicylate or capsaicin with Cannabis sativa.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: July 13, 2021
    Inventor: Bob Fuladi
  • Patent number: 11045483
    Abstract: The subject-matter of the present invention is the use of a therapeutic composition comprising, in an applying carrier, at least one essential oil for relieving muscle and/or joint pain in an animal subject, wherein said composition topically treats an area of the skin of said subject, characterized in that said composition comprises methyl salicylate, which constitutes, with at least one essential oil of the composition containing same in only a small amount or not at all, an active agent within which the rate of transport of the methyl salicylate through the skin is increased by virtue of the oil, which is an essential oil.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 29, 2021
    Assignee: AB7 INNOVATION S.A.S.U.
    Inventor: Rene Chelle
  • Patent number: 11007385
    Abstract: The invention describes methods and agents for inducing in the skin one or more effects selected from stimulating fibroblast migration, stimulating elastin production, reducing expression of inflammatory factors and upregulating specific genes, thereby preventing skin cell aging processes and repairing skin damage. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 18, 2021
    Assignee: REGENICS AS
    Inventors: Runhild Gammelsaeter, Jan Remmereit, Gry Kalstad Lonne, Camilla Margrethe Haglerod
  • Patent number: 10993910
    Abstract: A biopatch, a bioheater, a biosensor and a bioelectronic patch device are provided. The biopatch comprises a polymer film comprising a biopolymer and a drug loaded in the polymer film. The biopolymer may comprise one or more than one of a bioabsorbable polymer, a biodegradable polymer and a biocompatible polymer. The biopolymer may comprise oxidized starch. The drug may comprise a first drug chemically combined with the oxidized starch and a second drug physically combined with the oxidized starch. The bioheater comprises a heater comprising biometal. The biometal may comprise Mg or Fe. The heater can be controlled wirelessly by an alternating magnetic field.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: May 4, 2021
    Inventors: Daehyeong Kim, Seunghong Choi, Taeghwan Hyeon, Jongha Lee, Hyerim Cho, Hyunseon Seo
  • Patent number: 10998091
    Abstract: Aspects of the invention include systems for monitoring compliance of a patient with a patch dosage regimen and, where necessary, providing rapid, economical intervention when non-compliance is detected. In some instances, the systems include: a patch comprising an active agent and a patch tag; a reader configured to detect the patch tag; one or more processing devices; and a compliance determination module comprising a computer-readable storage medium comprising instructions that, when executed by the one or more processing devices, determine compliance information from data received from the reader. The compliance information includes data that may be employed to determine whether the patient is complying with the patch dosage regimen. Also provided methods of using the systems, e.g., to monitor patient compliance, as well as components of the systems, e.g., patches, readers, etc.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: May 4, 2021
    Inventor: Sandeep Patil
  • Patent number: 10987316
    Abstract: Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 27, 2021
    Inventors: Jun Liao, Takito Shima, Puchun Liu, Steven Dinh
  • Patent number: 10980753
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: April 20, 2021
    Inventors: Patrick Mohr, René Rietscher, René Eifler, Olga Bourquain
  • Patent number: 10963118
    Abstract: An electrode structure and a touch panel including the electrode structure are provided. The electrode structure includes a membrane layer and a metallic nanowires layer having metallic nanowires. A first portion of the metallic nanowires layer is covered by the membrane layer, and a second portion of the metallic nanowires layer is exposed out of the membrane layer. The membrane layer is made of a copolymer formed by mixing two or more materials having different functional groups.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: March 30, 2021
    Assignee: Cambrios Film Solutions Corporation
    Inventors: Chung-Chin Hsiao, Siou-Cheng Lien, Chia-Yang Tsai, Yi-Wen Chiu, Shu-Ping Hsu
  • Patent number: 10945945
    Abstract: Stabilized skin care compositions are described. The compositions comprise a fish oil component that yields a product of oxidation and the component is stabilized with a radical scavenger, a peroxide decomposer and hydroxylated fatty acid and/or a derivative thereof.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: March 16, 2021
    Assignee: CONOPCO, INC.
    Inventors: Marina Tomashevskaia, Hasiba Bekto